Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279162 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis
A Phase 3 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
NCT00279162 is a Phase 3 study that has completed, run by LEO Pharma. The registered enrollment target is 160 participants.
The verdict
NCT00279162, a Phase 3 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
Study Summary
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this time all patients will receive the gel containing both calcipotriene and betamethasone for 44 weeks. In addition, patients will receive an ointment containing both calcipotriene plus betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks. The objective is to study the short-term efficacy of the gel, and the short and long-term safety of the gel and the ointment.
Interventions
- DRUG Calcipotriene/betamethasone gel and ointment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279162
The ClinicalTrials.gov registry entry for NCT00279162 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Calcipotriene/betamethasone gel and ointment is the first listed.
NCT00279162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00279162 about?
NCT00279162 is a clinical study titled "Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis". Patients will receive either a gel containing both calcipotriene plus betamethasone or gel with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this time all patients will receive the gel containing both calcipotriene and betamethasone for 44 weeks. In addition, patie...
What is the current status of trial NCT00279162?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2005-12. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00279162?
The interventions under investigation include: Calcipotriene/betamethasone gel and ointment (DRUG).
Who is sponsoring clinical trial NCT00279162?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.